<DOC>
	<DOCNO>NCT02206425</DOCNO>
	<brief_summary>The goal clinical research study evaluate safety effectiveness ( good bad effect ) ixazomib give part combination therapy treat subject relapse ( subject whose disease come back ) refractory ( subject whose disease respond past treatment ) multiple myeloma . More specifically , study focus subject previously treat bortezomib ( Velcade® ) carfilzomib ( Kyprolis® ) show worsen myeloma receive either one drug combination therapy . This study Phase I/II . Ixazomib investigational drug , mean ixazomib currently test yet approve United States Food Drug Administration ( FDA ) subject relapse refractory multiple myeloma . Ixazomib new study drug belongs class bortezomib carfilzomib ; however , unlike bortezomib carfilzomib , ixazomib take mouth . Current study investigate ixazomib demonstrate safe bortezomib effective treatment multiple myeloma combination multiple myeloma medication , lenalidomide dexamethasone , prednisone melphalan .</brief_summary>
	<brief_title>Ixazomib Replacement Carfilzomib Bortezomib Multiple Myeloma Patients</brief_title>
	<detailed_description>This phase 1/2 , intra-patient , multicenter , open-label non-randomized study evaluate efficacy safety ixazomib replacement bortezomib carfilzomib among multiple myeloma ( MM ) patient fail proteasome inhibitor ( PI ) -containing combination regimen . Patients receive ixazomib week place bortezomib carfilzomib combination alkylating agent ( melphalan cyclophosphamide ) , anthracycline ( pegylated doxorubicin [ PLD ] ) , immunomodulatory agent ( lenalidomide ) , ascorbic acid and/or glucocorticosteroid ( dexamethasone , prednisone methylprednisolone ) administer use dose ( schedule ( ) last PI-containing regimen patient receive failed . The total number different prior bortezomib- carfilzomib-containing regimen evaluate 8 , reflect commonly use community follow : - bortezomib + melphalan + prednisone - bortezomib + cyclophosphamide + ascorbic acid - bortezomib + cyclophosphamide + dexamethasone - bortezomib + PLD + dexamethasone - bortezomib + dexamethasone - carfilzomib + dexamethasone - bortezomib + lenalidomide + dexamethasone - carfilzomib + lenalidomide + dexamethasone This study enroll 60 patient refractory bortezomib- carfilzomib-containing combination regimen , demonstrate progressive disease ( PD ) treat , relapse within 8 week last dose bortezomib carfilzomib last PI-containing combination regimen . Ixazomib replace bortezomib carfilzomib use PI-containing regimen patient failed.The study consist : 1 ) screening period ; 2 ) eight 28-day treatment cycle ; 3 ) maintenance period ; 4 ) final assessment occur 28 day end last treatment cycle ; 5 ) follow-up period . Ixazomib administer PO 4 mg Days 1 , 8 15 28-day cycle patient enrol five regimen ( bortezomib+ melphalan + prednisone , bortezomib + dexamethasone , carfilzomib + dexamethasone , bortezomib + lenalidomide + dexamethasone , carfilzomib + lenalidomide + dexamethasone ) . Subjects regimens receive 4 mg ixazomib begin trial continue length study , unless suffer adverse event require dose reductions.For three regimen , bortezomib+ cyclophosphamide + dexamethasone , bortezomib + cyclophosphamide + ascorbic acid , bortezomib + PLD + dexamethasone , MTD ixazomib unknown intra-patient dose escalation perform determine specific MTD . For three regimen , ixazomib administer Days 1 , 8 15 28-day cycle start dose 3 mg Cycle 1 , intra-patient dose-escalation proceed 4 mg Cycle 2 . All agent administer schedule dose intensity last PI-containing treatment patient fail .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Key 1 . Male female patient 18 year old 2 . Patients must diagnosis MM , base standard criteria2 follow : Major criterion : 1. plasmacytoma tissue biopsy 2. bone marrow plasmacytosis ( great 30 % plasma cell ) 3. monoclonal immunoglobulin spike serum electrophoresis IgG great 3.5 g/dL IgA great 2.0 g/dL ; kappa lambda light chain excretion great 1 g/day 24 hour urine protein electrophoresis Minor criterion : 1. bone marrow plasmacytosis ( 10 % 30 % plasma cell ) 2. monoclonal immunoglobulin present less magnitude give major criterion 3. lytic bone lesion 4. normal IgM le 50 mg/dL , IgA le 100 mg/dL , IgG le 600 mg/dL Any follow set criterion confirm diagnosis multiple myeloma : 2 major criterion major criterion 1 plus minor criterion 2 , 3 , 4 major criterion 3 plus minor criterion 1 3 minor criterion 1 , 2 , 3 , 1 , 2 , 4 3 . Currently progressive MM previously progress currently progress receive within 8 week receive bortezomib carfilzomib part combination treatment . MM patient demonstrate refractory disease , define , eligible enrollment provide fulfill eligibility criterion : Patients refractory bortezomib carfilzomib combination regimen , progress currently receive bortezomib carfilzomib combination treatment , within 8 week last dose . Prior treatment four day less total 400 mg prednisone ( equivalent potency another steroid ) MM consider regimen 4 . Patients bortezomibcontaining regimen must administer least 4 dos minimum 1.0 mg/m2 28days cycle . Subjects must receive least one cycle meeting definition show PD consider eligible 5 . Patients carfilzomibcontaining regimen must receive least 6 dos least 27 mg/m2 28 day per cycle . Subjects must receive least one cycle meeting definition show PD consider eligible 6 . Progressed one specific bortezomib carfilzomibcontaining regimen list page 44 . Although bortezomib carfilzomibcontaining combination regimen otherwise identical except PI result ixazomib regimen , enrol separately safety/efficacy separately determine , thereby allow comparison base prior PI subject expose part regimen fail ( carfilzomib vs. bortezomib ) 7 . Patient may receive carfilzomib bortezomibcontaining regimen time may receive nonproteasome inhibitorcontaining intervene treatment Key 1 . Patient diagnose : 1 . Plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( M protein ) skin change ( POEMS ) syndrome.3 2 . Primary amyloidosis 3 . Plasma cell leukemia 4 . Severe hypercalcemia , i.e. , serum calcium = 12 mg/dL ( 3.0 mmol/L ) correct albumin 2 . Nonhematologic malignancy within past 5 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas 3 . Impaired cardiac function clinically significant cardiac disease , include myocardial infarction within 6 month prior enrollment , New York Heart Association ( NYHA ) Class II great heart failure , uncontrolled angina , clinically significant pericardial disease , severe uncontrolled ventricular arrhythmia , echocardiogram multigated acquisition scan ( MUGA ) evidence leave ventricular ejection fraction ( LVEF ) institutional normal within 28 day prior enrollment , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant 4 . Patient peripheral neuropathy grade 3 high Grade 2 pain clinical examination screen period 5 . Patient receive follow prior therapy : 1 . Chemotherapy within 21 day enrollment ( 6 week nitrosoureas ) 2 . Corticosteroids ( &gt; 10 mg/day prednisone equivalent ) within 21 day enrollment 3 . Immunotherapy antibody therapy well thalidomide , pomalidomide , lenalidomide , arsenic trioxide , carfilzomib , bortezomib within 21 day enrollment 5 . Known allergy study medication , analogue , excipients various formulation agent 6 . Known GI disease GI procedure could interfere oral absorption tolerance ixazomib include difficulty swallowing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>Relapsed/refractory</keyword>
	<keyword>Ixazomib</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>Oral</keyword>
</DOC>